SIETES :: 93011 citas

Resultados de la búsqueda por DENSIDAD MINERAL ÓSEA REFINAR BÚSQUEDA

1.

Anónimo. FDA approves elagolix for endometriosis pain. DIA Daily 2018:25 de julio. [Ref.ID 102722]

2.

Anónimo. Strontium ranelate discontinued. Prescribing Advice for GPs 2017:1. [Ref.ID 101637]

3.

Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, Sadler S, Wong R, Campbell F, Stevenson M, Strong M, Selby P, Gittoes N. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technol Assess 2016;20:1-406. [Ref.ID 101044]

4.

Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CAF, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 2016;375:1532-43. [Ref.ID 100908]

5.

Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo A, Alexandersen P, Zerbini CAF, Hu M-y, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C, for the ACTIVE Study Investigators. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 2016;316:722-33. [Ref.ID 100710]

6.

Cappola AR, Shoback DM. Osteoporosis therapy in postmenopausal women with high risk of fracture. JAMA 2016;316:715-6. [Ref.ID 100709]

7.

Munson JC, Bynum JPW, Bell J-E, Cantu R, McDonough C, Wang Q, Tosteson TD, Tosteson ANA. Patterns of prescription drug use before and after fragility fracture. JAMA Intern Med 2016;176:1531-8. [Ref.ID 100584]

8.

Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippi K, Rubin S, Sturtz K, Wolff AC, Winer E, Hudis C, Stopeck A, Beck JT, Kaur JS, Whelan K, Tu D, Parulekar WR. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 2016;375:209-19. [Ref.ID 100399]

9.

Torjesen I. Extra five years of aromatase inhibitors increases disease-free survival in breast cancer. BMJ 2016;353:i3153. [Ref.ID 100380]

10.

Paskins Z, Warburton L. Bisphosphonates beyond five years. BMJ 2016;352:i264. [Ref.ID 100306]

11.

Yeh MW, Zhou H, Adams AL, Ituarte PHG, Liu IA, Haigh PI. The relationship of parathyroidectomy and bisphosphonates with fracture risk in primary hyperparathyroidism: an observational study. Ann Intern Med 2016:5 de abril. [Ref.ID 100114]

12.

Moro Álvarez MJ, Neyro JL, Castañeda S. Vacaciones terapéuticas en osteoporosis: estrategia en el tratamiento a largo plazo con bifosfonatos. Med Clin (Barc) 2016;146:24-9. [Ref.ID 99986]

13.

Anónimo. Prevención de fracturas osteoporóticas y duración del tratamiento. Boletín Terapéutico Andaluz 2015;30:1. [Ref.ID 99827]

14.

Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie S-A. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 2015;386:1147-55. [Ref.ID 99538]

15.

Anónimo. Invokana and Invokamet (canagliflozin): drug safety communication - New information on bone fracture risk and decreased bone mineral density. U.S. Food and Drug Administration 2015:10 de septiembre. [Ref.ID 99461]

16.

Hansen KE, Johnson RE, Chambers KR, Johnson MG, Lemon CC, Vo TN, Marvdashti S. Treatment of vitamin D insufficiency in postmenopausal women: a randomized clinical trial. JAMA Intern Med 2015;175:1612-21. [Ref.ID 99457]

17.

Overton ET, Chan ES, Brown TT, Tebas P, McComsey GA, Melbourne KM, Napoli A, Hardin WR, Ribaudo HJ. Vitamin D and calcium attenuate bone loss with antiretroviral therapy initiation: a randomized trial. Ann Intern Med 2015;162:815-24. [Ref.ID 99296]

18.

Anónimo. Osteoporosis postmenopáusica: un consenso necesario. Infac: Información Farmacoterapéutica de la Comarca 2015;23:27-32. [Ref.ID 99199]

19.

Greenspan SL, Perera S, Ferchak MA, Nace DA, Resnick M. Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial. JAMA Intern Med 2015;175:913-21. [Ref.ID 99183]

20.

Anónimo. Traitements des cancers de l'enfance: effets indésirables à long terme. Prescrire 2015;35:348-52. [Ref.ID 99136]